Table 1 Clinical characteristics of patients with Crohn’s disease and the control group
Endoscopic Remission n = 27 | Mild activity n = 21 | Moderate to severe activity n = 32 | P value | |
|---|---|---|---|---|
Gender: | ||||
Male | 11 (40.7%) | 15 (71.4%) | 16 (50.0%) | |
Female | 16 (59.3%) | 6 (28.6%) | 16 (50.0%) | |
Age (P 25–75) | 40,0 (29.0–50.0) | 41 (23.5–50.0) | 32,5 (24–36.8) | 0.102* |
Montreal Classification | n (%) | n (%) | n (%) | |
Age at diagnosis | ||||
A1 (≤16 years) | 3 (11.1) | 1 (4.8) | 4 (12.5) | 0.149** |
A2 (17–40) | 16 (59.3) | 15 (71.4) | 25 (78.1) | |
A3 (>40 years) | 8 (29.6) | 5 (23.8) | 3 (9.4) | |
Disease Phenotype | ||||
B1 | 5 (18.5) | 4 (19.0) | 11 (34.4) | |
B1p | 5 (18.5) | 6 (28.6) | 9 (28.1) | |
B2 | 8 (29.7) | 5 (23.8) | 9 (28.1) | 0.342** |
B2p | 2 (7.4) | 1 (4.8) | 1 (3.1) | |
B3 | 5 (18.5) | 4 (19.0) | 0 (0) | |
B3p | 2 (7.4) | 1 (4.8) | 2 (6.3) | |
Location of disease | ||||
L1 | 10 (37.0) | 8 (38.1) | 7 (21.9) | |
L2 | 4 (14.8) | 4 (19.0) | 8 (25.0) | |
L3 | 11 (40.8) | 8 (38.1) | 17 (53.1) | 0.628** |
L1+ L4 | 2 (7.4) | 1 (4.8) | 0 (0) | |
Medication | ||||
5-ASA | 14 (51.9) | 12 (57.1) | 14 (43.8) | |
Thiopurine | 19 (70.3) | 14 (66.7) | 20 (62.5) | |
Anti-TNF | 6 (22.2) | 0 (0) | 11 (34.4) | |
Antibiotics | 4 (14.8) | 9 (42.9) | 2 (6.3) | |
Prednisone | 9 (33.3) | 7 (33.3) | 19 (59.4) | |
Methotrexate | 0 (0) | 0 (0) | 1 (3.1) | |
Tacrolimus | 0 (0) | 0 (0) | 1 (3.1) | |